Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

Next Previous
Trial Profile

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flecainide/modafinil (Primary)
  • Indications Narcolepsy
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Theranexus

    • Most Recent Events

    • 25 Sep 2019 Status changed from recruiting to active, no longer recruiting.
    • 09 Sep 2019 Planned End Date changed from 1 Oct 2019 to 1 Feb 2020.
    • 09 Sep 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top